Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1‐mutant soft‐tissue sarcoma of childhood

The myogenic differentiation 1 gene (MYOD1) p.L122R somatic mutation was first discovered in a subset of clinically aggressive embryonal rhabdomyosarcomas and has since been described in both pediatric and adult spindle cell/sclerosing rhabdomyosarcomas. Relatively little is known about the clinical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pathology 2021-09, Vol.255 (1), p.52-61
Hauptverfasser:	Ting, Michelle A, Reuther, Jacquelyn, Chandramohan, Raghu, Voicu, Horatiu, Gandhi, Ilavarasi, Liu, Meng, Cortes‐Santiago, Nahir, Foster, Jennifer H, Hicks, John, Nuchtern, Jed, Scollon, Sarah, Plon, Sharon E, Chintagumpala, Murali, Rainusso, Nino, Roy, Angshumoy, Parsons, D Williams
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Adolescent AKT protein Animals Antineoplastic Agents - pharmacology Child Childhood Children Copy number DNA sequencing Female Genomic analysis Genomics Heterozygosity Humans Imidazoles - pharmacology Loss of heterozygosity Male Mice Mutants Mutation Mutation hot spots MyoD Protein - genetics MYOD1 Patients patient‐derived xenograft pediatric soft‐tissue sarcoma Pediatrics PTEN protein Quinolines - pharmacology Rhabdomyosarcoma Rhabdomyosarcoma - genetics Rhabdomyosarcoma - pathology Sarcoma Sclerosis Soft Tissue Neoplasms - genetics Soft Tissue Neoplasms - pathology spindle cell/sclerosing rhabdomyosarcoma TOR protein Tumors Xenograft Model Antitumor Assays Xenografts Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!